Elsevier

The Journal of Pediatrics

Volume 160, Issue 2, February 2012, Pages 193-198
The Journal of Pediatrics

Commentary
Over-Prescription of Acid-Suppressing Medications in Infants: How It Came About, Why It’s Wrong, and What to Do About It

https://doi.org/10.1016/j.jpeds.2011.08.067Get rights and content

First page preview

First page preview
Click to open first page preview

References (50)

  • D.J. Hill et al.

    Role of food protein intolerance in infants with persistent distress attributed to reflux esophagitis

    J Pediatr

    (2000)
  • P. Sherman et al.

    A global evidence-based consensus on the definition of gastroesophageal reflux disease in children

    Am J Gastroenterol

    (2009)
  • S. Fiedorek et al.

    Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease

    J Pediatr Gastroenterol Nutr

    (2005)
  • V. Tolia et al.

    Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children

    J Pediatr Gastroenterol Nutr

    (2002)
  • B.D. Gold et al.

    Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease

    J Pediatr Gastroenterol Nutr

    (2007)
  • V. Tolia et al.

    Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study

    BMC Pediatr

    (2010)
  • R. Baker et al.

    Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis

    Clin Pediatr (Phila)

    (2010)
  • Hassall E, Shepherd R, Koletzko S, Radke M, Henderson C, Lundborg P. Prospective long-term maintenance treatment with...
  • E. Hassall et al.

    Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration

    J Pediatr

    (2007)
  • Y. Vandenplas et al.

    Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition

    J Pediatr Gastroenterol Nutr

    (2009)
  • G. Boccia et al.

    Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?

    Am J Gastroenterol

    (2007)
  • E. Hassall

    Outcomes of fundoplication: causes for concern, newer options

    Arch Dis Child

    (2005)
  • J.J. Barron et al.

    Proton pump inhibitor utilization patterns in infants

    J Pediatr Gastroenterol Nutr

    (2007)
  • S.R. Orenstein et al.

    Infants and proton pump inhibitors: tribulations, no trials

    J Pediatr Gastroenterol Nutr

    (2007)
  • A.J. Martin et al.

    Natural history and familial relationships of infant spilling to 9 years of age

    Pediatrics

    (2002)
  • Cited by (57)

    • Trends and Correlates of Early-Life Exposure to Acid-Suppressant Therapy in Israel (2005-2020)

      2023, Journal of Pediatrics
      Citation Excerpt :

      Our study has several strengths. First, we used contemporary data of treatment patterns up to the year 2021, reflecting that despite previous calls to reduce overprescribing,21 the increasing trend continues to date. Second, patients’ clinical and demographic features were explored, detecting risk factors that shed light on potentially behavioral aspects of treatment initiation.

    • Risk Factors for Community-Associated Clostridium difficile Infection in Children

      2017, Journal of Pediatrics
      Citation Excerpt :

      We found that the odds of CA-CDI development following proton pump inhibitor and H2 receptor antagonist exposure were similar to that seen with antibiotic exposures. Given the high frequency with which these medications are prescribed in pediatrics for conditions such as physiologic reflux, these exposures may be a contributor to the increasing number of CA-CDI cases seen in children.22,23 Although C difficile remains a common hospital-associated infection, with great emphasis placed on the importance of infection control measures used to prevent spread in the inpatient setting, our results indicate that many CA-CDI cases may be the result of transmission in the outpatient healthcare setting.

    View all citing articles on Scopus

    E.H. received a clinical research grant from AstraZeneca Canada and serves as a consultant for Takeda Pharmaceuticals.

    View full text